免疫性血小板缺血的问题是对eltrombopag和romiplostim两种药物都不耐药的
Hanny Al-Samkari1, Alexandra Schifferli2, Tomas J Gonzalez-Lopez3
1Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
British journal of haematology
|February 6, 2024
概括
耐受性较高的免疫性血小板衰竭对血小板蛋白受体激动剂具有显著的临床挑战. 这篇评论回顾了难以治疗的病例的发现,并建议了未来的管理策略.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 对多种治疗耐药的原发性免疫血小板缩 (ITP) 构成了临床挑战.
- 血栓形成素受体激动剂 (TPO-RAs) 是标准疗法,但有些患者没有充分的反应.
- 难以治疗的ITP需要进一步调查患病率和管理.
研究的目的:
- 讨论和语境化穆利斯等人的发现. 关于难以治疗的原发性免疫性血小板缺血症.
- 探索对TPO-RAs耐火性ITP的流行率和负担.
- 为了解决这些具有挑战性的患者的管理前进提供见解.
主要方法:
- 莫利斯等人发表的关于CARMEN-France注册表结果的评论.
- 对患有难以治疗的原发性免疫性血小板缺血症的成年患者的数据分析.
- 审查现有的文献和临床实践指南.
主要成果:
- 莫利斯等人进行的研究. 这篇文章强调了难以治疗的ITP的流行和负担.
- 很大一部分ITP患者仍然对多种TPO-RA疗法不耐药.
- 了解这些患者的特征对于有效管理至关重要.
结论:
- 对多个TPO-RAs耐药的免疫性血小板缩是一个重要的临床问题.
- 需要进一步的研究和定制策略来管理这些患者.
- 评论提供了一个框架来应对难以治疗的ITP的挑战.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
01:24Disorders of Hemostasis
915
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
915